Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer

NCT07393048 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT07393048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07393048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer
Lead sponsor
Beijing Friendship Hospital
Phase
Observational
Overall status
Recruiting
Start date
February 15, 2026
Completion date
December 31, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal cancer (larc)